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Abstract
Introduction: Heterogeneity of cartilage tumours may confound accurate diagnosis and grading
resulting in under and over treatment. Improved preoperative assessment of malignancy and grade
would be invaluable for developing a rational plan for treatment. We examined correlations
between nuclear tracer avidity and malignancy grade in cartilage tumours.
Methods: Between 1996 and 2000, 92 consecutive patients with cartilaginous tumours (50 benign,
42 non-metastatic malignant) underwent nuclear scanning. Thallium-201 (TL-201) and pentavalent
dimercaptosuccinic acid (DMSAV) were used as nuclear isotopes. Scanning with these agents was
performed on separate days 48 hours apart. Static and SPECT images were obtained at 30 m and
4 h after injection of nuclear tracer. Pathology review was undertaken blinded to the results of the
nuclear scans and correlations between histologic results and trace uptake at 4 hours examined.
Results: 25 patients with negative DMSAV had benign tumours. 15/17 tumours with positive TL-
201 had malignant tumours. 11/13 patients with both positive DMSAV and TL-201 scans had
intermediate or high grade tumours and 4 of these developed metastases. We have developed an
algorithm for the management of patients with tumours that aims to avoid over treatment of low
grade tumours and under treatment of high grade tumours.
Conclusion: Functional nuclear scanning with TL-201 and DMSAV complements other imaging
modalities in the management of cartilaginous tumours.
Background
Traditionally, the determination of malignancy and its
grade in cartilage tumours has been from the combination
of history, radiographic features with or without com-
puted tomography and histologic examination [1-3].
More recently, magnetic resonance imaging has also been
employed [4-6]. However, cartilage tumours are recog-
nized for their histologic heterogeneity [7-9] and bizarre
physical features, such that reliance on anatomic imaging
and accuracy of biopsy alone for interpretation of state of
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malignancy or benignity may be misleading. While the
recognition of high grade malignancy is not difficult, the
differentiation between benign and low grade (grade I)
tumours can present a diagnostic dilemma [10,11]. Such
a dilemma may lead inadvertently to under-or over-treat-
ment of cartilage tumours.
Functional nuclear scans employ isotopes that become
substrates for various cellular metabolic cycles and there-
fore, are useful for determining the metabolic activity in
these tissues [12]. Given that malignant tumours are more
metabolically active than benign tumours, and that there
is a relationship between grade of malignancy and meta-
bolic activity, functional nuclear scans may help to differ-
entiate between cartilage tumours of varying metabolic
activity, which in turn, may shed some light on their state
of malignancy.
We now report our experiences with 2 radio-siotopes,
Thallium-201 (Tl-201) and pentavalent dimercaptosuc-
cinic acid (DMSAV) for determining the metabolic activity
of cartilage tumours, and their value in differentiating
between malignant and benign cartilage tumours in 92
consecutive cartilage tumours. We describe their role in




Between January 1997 and December 2000, 92 consecu-
tive patients were referred to our institution for investiga-
tion and management of suspected chondral tumours.
There were 50 females and 42 males with a median age of
45 years (range 16–87 years).
Tumours were located in the humerus (17), chest wall (3),
femur (27), hand (3), knee (3), vertebra (1), scapula (7),
tibia (16), pelvis (9), foot (4), radius (2). All patients had
previously unoperated tumours and no patient presented
with metastases.
Investigations
All patients were examined with plain radiographs, com-
puted tomography and magnetic resonance imaging.
From 1997 onward, TL-201 and/or DMSAV scans were
also performed on patients with suspected chondral
tumours.
Tl-201 and DMSAV scintiigraphy were conducted at two
centers (SVH, PMCI) with similar imaging protocols. All
studies were conducted using a gamma camera. A pre-
determined dose of radioisotope was administered intra-
venously and scintigraphic images obtained at 30 minutes
(early phase) and 3–4 hours (late phase) after injection in
all cases. Early phase static images were acquired over the
area of interest and late phase images consisted of whole
body imaging and SPECT over the area under investiga-
tion. A low energy high resolution, parallel-hole collima-
tor was used and image acquired in a 128 × 128 matrix for
5 minutes. A simple grading system was devised for late
phase isotope uptake with NO UPTAKE indicating no
tumour uptake greater than background activity and
INCREASED UPTAKE indicating definite activity greater
than the background level. The background level referred
to is that of the tissue within which the tumour arose, that
is, bone. We selected the late phase results for correlation
with the results of histological examination of the surgical
specimens because early uptake at 30 minutes may also
represent peritumoural inflammation or vascularity,
which may confound the interpretation of results. In con-
trast, late phase uptake represented true tumour uptake of
isotope.
Tumours
The pathologist (JS) is the designated lead pathologist on
the Victorian Bone Tumour Registry. For the purpose of
this study, assessments of surgical tissue and histologic re-
evaluation were conducted without prior knowledge of
the results of the functional nuclear scans. There were 50
benign tumours and these consisted of enchondromata
(29), osteochondromata (17), chondroblastoma (3), and
chondromyxoid fibroma (1). There were 42 malignant
tumours and these consisted of 38 central chondrosar-
coma and 4 dedifferentiated chondrosarcoma. Of these
malignant tumours, 22 were graded as grade I, 12 as grade
II and 8 as grade III according to.
Treatment
All tumours in this study were treated with excision. In
those tumours that were considered to be benign or grade
1 malignancy as based on history, examination, plain
radiography, magnetic resonance imaging and functional
scanning, were treated by careful intralesional curettage,
burring with a high speed dental burr, pulsatile lavage,
chemical cautery with phenol and then the defect filled
with polymethylmethacrylate cement. In those tumours
that were considered to be clearly malignant and inter-
preted as grade 2 and higher or if the functional nuclear
scans showed significant uptake, wide resection was
employed.
Because of the histologic heterogeneity of cartilage
tumours, the majority of tumours were not biopsied prior
to definitive surgery. Biopsy was considered if there was
doubt about the diagnosis, or if the anticipated treatment
was potentially far greater than may have been required. If
biopsy was preferred but could not be safely performed
preoperatively, for example, a periacetabular tumour, fro-
zen section drill biopsy would be conducted as part of the
initial surgical approach to the tumour.International Seminars in Surgical Oncology 2004, 1:10 http://www.issoonline.com/content/1/1/10
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Follow-up
No patients were lost to follow-up. Patients with malig-
nant tumours were reviewed every 3 months for the first 2
years and 6 monthly after that for a further 2 years with a
plan for yearly review for the following 4 years. Computed
tomography of the chest was performed every 6 months,
and plain radiographs obtained of the operated area at
each visit.
The median follow-up was 3.7(0–6) years. At last review,
85 patients were alive without disease, 2 were alive with
pulmonary metastases. 3 patients had died of metastatic
disease, one patient died from intraoperative complica-
tions and 1 patient died from a pulmonary embolus 1
month after surgery. There were no local recurrences.
Results
Thallium scans
Eighty seven of ninety two patients underwent thallium
scanning. Of these, 17 patients had increased uptake on
the delayed scans, and 70 patients had no uptake on the
delayed scans.
DMSA(V) scans
Eighty three of ninety two patients underwent DMSA(V)
scanning. Of these, fifty eight patients had increased
uptake on the delayed scans and twenty five patients had
no uptake on the delayed scans.
Combined thallium and DMSA(V) scans
Seventy eight of ninety two patients had both thallium
and DMSA(V) scanning. There was no uptake with Thal-
lium and DMSA(V) scanning in twenty patients. Thallium
scanning was negative and DMSA(V) was positive in forty
five patients. There was uptake on both Thallium and
DMSA(V) scanning in 13 patients. There was no case
where there was thallium uptake without DMSA(V)
uptake.
Correlation between functional scanning and state of 
benignity /malignancy of tumours
a. Thallium scans Of the 50 benign tumours, 45 underwent
thallium scanning. Forty-three tumours had negative
scans and 2 had positive scans. Of the 42 malignant
tumours, 27 had negative thallium scans and 15 had pos-
itive scans.
b. DMSA(V) scans Of the 50 benign tumours, 47 had
DMSA(V) scans. Twenty five of these tumours had nega-
tive scans and 22 had positive scans. Of the 42 malignant
tumours, 36 had DMSA(V) scans. All 36 of these were pos-
itive. No malignant tumour was DMSA(V) negative.
c. Combined thallium and DMSA(V) scans There 78
tumours that were scanned with both thallium and
DMSA(V). Of the 42 benign tumours, 2 had positivity for-
both thallium and DMSA(V), 20 had positivity only for
DMSA(V) and 20 had no uptake on either scan.
Of the 36 malignant tumours that were scanned with both
isotopes, 11 showed positivity for both thallium and
DMSA(V), while 25 tumours showed positivity for
DMSA(V) only. No malignant tumour was negative to
thallium scanning.
Correlation between functional scanning and tumour 
grade in 42 choindrosarcomas
a. Thallium scans Of the 42 chondrosarcomas, 7 grade II
and 8 grade III tumours had positive thallium uptake. No
grade I tumour had thallium uptake. Twenty two grade I
tumours, and 5 grade II tumours showed no uptake.
b. DMSA(V) scans Thirty six of the 42 chondrosarcomas
had DMSA(V) scans. All were positive (20 grade I, 11
grade II, 5 grade III). No chondrosarcoma was DMSA(V)
negative.
Correlation between functional scanning and metastasis
No patient with a negative thallium scan developed
metastasis. Six of seventeen patients with positive thal-
lium scans developed metastases. In contrast, four of fifty
eight patients with positive DMSA(V) scans developed
metastases. In patients where both scans were performed,
four of thirteen patients developed metastases.
Discussion
Anatomic imaging such as computed tomography [13]
and magnetic resonance imaging [4-6,14] provide excel-
lent morphologic delineation and localisation of bone
tumours. These tests are invaluable in the surgical plan-
ning for patients with musculoskeletal tumours However,
these tests do not always give an indication of the biologic
behaviour of the tumour, particularly if there are subtle-
ties between benign and low grade malignant states [15].
Cartilaginous tumours of bone are characterized by radio-
logic and histologic heterogeneity [7,8] that may give rise
to diagnostic dilemas. Benign tumours such as enchon-
dromas and osteochondromas may appear large and
bizarre giving an impression of biologic aggressiveness,
particularly those in the hand, while some chondrosarco-
mas such as a clear cell chondrosarcoma may be small,
well defined, slow growing and apart from osteolysis have
no other hallmark of malignancy [16-18] such as cortical
destruction or soft tissue extension to express its malig-
nant phenotype. One of the major difficulties in ortho-
paedic oncology is the differentiation between
enchondroma and grade 1 chondrosarcoma [19].
Conventional technetium monodiphosphonate skeletal
scans are employed to identify uni-or multifocal diseaseInternational Seminars in Surgical Oncology 2004, 1:10 http://www.issoonline.com/content/1/1/10
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when bone tumours are suspected [12]. For positivity, this
scanning modality relies on the interactions between
tumour and host bone that incite an osteoblastic response
by adjacent bone and does not necessarily imply malig-
nancy. For example, enchondroma and chondrosarcoma
frequently demonstrate a similar uptake of nuclear tracer,
without differentiating between benignity and malignanc.
Reliance on preoperative histologic diagnosis for deter-
mining the nature of a cartilage lesion can also be diffi-
cult. Biopsy of a suspicious cartilage tumour is most
helpful when clear malignancy is demonstrated because a
benign finding does not necessarily exclude malignancy.
The histologic heterogeneity of cartilage tumours, how-
ever, is well recognized and unless the biopsy accurately
targets the most malignant part of the tumour, there is a
risk that the histologic diagnosis may under-report the
state of malignancy if this should exist.
Functional nuclear scans reflect the metabolic activity of
tumours and may provide important information regard-
ing their biologic behaviour. In this regard, hypermeta-
bolic tumour tissue is likely to be more active than
surrounding normal tissue and this difference may be val-
uable for distinguishing between benign and malignant
tumours. Similarly, when dealing with grades of malig-
nancy, a higher level of metabolic activity may be
expected from high grade tumours in comparison to
lower grade counterparts. Since the late 1970s, thallium
(Tl-201) scanning has been used extensively as a safe
method to assess ventricular function in patients with
myocardial ischaemia and the results have been inter-
preted as reflecting relative levels of myocardial metabolic
activity. As Tl-201 is a potassium analogue, its uptake into
cells depends on the sodium potassium ATPase depend-
ent pump. Tl-201 is a readily available, cyclotron pro-
duced radionuclide that decays by electron capture with a
half-life of approximately 73 hours. The liver, spleen, kid-
neys, myocardium, thyroid, choroids plexus of the lateral
ventricles and testis normally demonstrate avidity for Tl-
201, with very minimal uptake in healing surgical
wounds. Tl-201 is thought to accumulate less well within
connective tissue, which contains inflammatory cells and
almost undetectable in necrotic tissue. Localization of Tl-
201 within tumours appears to be influenced by tumour
vascularity, tumour cellularity, the metabolic rate of the
tumour and the histological type of tumour. Thallium
uptake studies [20-23] in patients with bone tumours
have been used to predict response to preoperative chem-
otherapy by correlating the histological degree of tumour
necrosis to changes in Tl-201 uptake. The correlation
between thallium uptake and tumour metabolic activity,
thus makes it a good candidate tracer to assess malignancy
in chondromatous tumours. 99Tcm-Dimercaptosuccinic
acid (DMSA) is another readily available isotope, which
was first described as an isotopic agent for investigating
the renal parenchyma in a variety of disease entities [24-
26]. Subsequently, the pentavalent form of 99Tcm-dimer-
captosuccinic acid (99Tcm-(V)DMSA) developed a recog-
nised role for imaging medullary thyroid carcinoma, [27-
30] and this role was further investigated in relation to
assessing bone metastases and other neoplastic condi-
tions such as multiple myeloma, osteosarcoma and chon-
drosarcoma. [31-33]; [28,34]. Of note, uptake of
DMSA(V) is reported to be absent in vertebral collapse
and osteoarthritis [35].
Our study has demonstrated that the combined use of Tl-
201 and DMSA(V) scanning may be correlated with the
benignity, malignancy and grade of cartilaginous
tumours. For a tumour that is hetereogeneous not only on
radiologic but also pathologic appearance, the use of
functional nuclear scanning may help to differentiate par-
ticularly between the low grade and benign lesions. Of
note, no malignant lesion had a negative DMSA(V) scan,
and only 2 out of 45 benign tumours showed thallium
uptake in our study.
While this modality of investigation does not replace the
value of combining elements from the clinical presenta-
tion, plain radiographic changes and pathology, func-
tional nuclear scanning may increase the confidence of
diagnosing a low grade or benign tumour, and the availa-
bility of information preoperatively may also be helpful
for tumours that are deeply situated and difficult to
biopsy. With regard to biopsy, localized thallium or
DMSA(V) positivity may be useful for guiding tissue sam-
pling from the most metabolically active site, thus
enhancing the procurement of potentially the most
aggressive/malignant part of the tumour [12].
Although, the median duration of follow up in this study
was limited to 3.7 years, the high proportion of metastases
in patients whose sarcomas were thallium positive may
suggest a role for thallium scanning as a prognostic indi-
cator for metastasis in chondrosarcoma. Interestingly, the
combination of DMSA(V) with thallium scanning did not
improve the prognostic value for metastases. This may be
attributed to the fact that the spread of DMSA(V) positiv-
ity amongst the tumours was greater than thallium posi-
tivity, whereas the latter was positive only in patients with
grade II and III chondrosarcomas, which are the ones that
mainly metastasise.
We cannot explain why 2 out of 45 benign tumours were
thallium positive. The specimens were reviewed by a
panel of pathologists expert in bone pathology and none
conferred a diagnosis of sarcoma. In both of these cases,
DMSA(V) positivity was also observed. It is important to
note that these tumours occurred in the hand and foot,International Seminars in Surgical Oncology 2004, 1:10 http://www.issoonline.com/content/1/1/10
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although not part of the syndrome of enchondromatosis.
It is appreciated that small bone enchondromata may
behave locally in a very aggressive manner without any
cytologic evidence of malignancy [19]. However, small
bone chondrosarcoma are also know to be fatal and care-
ful inspection of imaging and pathology is required to
ensure distinction between benign and malignant lesions
which may behave similarly [36,37]. No conclusion can
be drawn about the biologic significance of our finding of
2 benign small bone tumours with thallium uptake, in
view of the very small numbers of these in our study. One
patient had a small toe amputation and the other had cur-
retage, chemical cautery and cementation of a phalangeal
lesion. Neither have represented with local or systemic
recurrence of disease.
As a result of this study, we now undertake the following
sequence of scanning and treatment (Figure 1). All
patients with a suspected chondral tumour would
undergo a DMSA(V) scan. If this is negative, no further
scanning is performed and the tumour is regarded as
benign because our study had indicated that no malignant
tumour had a negative DMSA(V) scan. These tumours
would then be treated on their individual merits. If there
is uptake on the delayed DMSA(V) scans our study had
indicated that half of these are likely to be malignant
therefore, patients would undergo thallium scanning. If
there is no uptake, then based upon our study, the result
would be interpreted as benign cartilage tumour or grade
1 chondrosarcoma. Patients may then undergo intrale-
sional curettage with chemical cautery and cementation or
wide excision. If there is uptake on the thallium scan, our
study demonstrated that there is a very high likelihood
that these tumours would be grade II or III and a wide
excision would be recommended.
Algorithm for the use of DMSA(V) and thallium scanning for cartilaginous tumours Figure 1
Algorithm for the use of DMSA(V) and thallium scanning for cartilaginous tumours. Thal : Thallium-201; DMSA(V) : Pentavalent 
dimercaptosuccinic acid +ve : positive uptake; -ve : no uptake.International Seminars in Surgical Oncology 2004, 1:10 http://www.issoonline.com/content/1/1/10
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Surgical treatment for cartilage lesions vary widely [38].
Intralesional curettage together with local adjuvant treat-
ment is often recommended for benign tumours but the
management of chondrosarcoma follows the same princi-
ples as espoused for all sarcomas [39,40]. Wide resection
with a cuff of normal tissue radially and axially around the
tumour is encouraged. The importance of good margins is
highlighted by the predilection for local recurrence of
incompletely excised chondrosarcoma [41-43], and also
because of the risk of chondrosarcomas recurring at a
higher maliginancy grade with its associated increased risk
of metastasis [44]. Inaccurate diagnosis and or grading
may thus result in under- or over treatment of cartilage
neoplasms that may later manifest as troublesome local
recurrence or unnecessary loss of function from ablative
surgery.
The management of grade 1 tumours remains controver-
sial. Some authors have recommended intralesional cur-
retage, adjuvant treatment and cementation for these
lesions [45,46]. In a series of 40 enchondromata and low
grade chondrosarcomas, Bauer et al. observed a local
recurrence of 0.09 over 10 years using this modality of
treatment. In all cases, local control was subsequently
achieved by repeating the earlier surgery on the recur-
rence. Neither recurrence occurred as a higher grade of
tumour. In contrast, some have recommended wide exci-
sion of grade I lesions and so called "borderline" chond-
rosarcoma for fear of tumour recurrence at a higher grade,
which would portend toward a poorer outcome [47,48].
The relationship between thallium positivity and higher
grades of chondrosarcoma in our study suggests that it
would be important to review in a prospective manner the
outcome of surgery based upon our algorithm of preoper-
ative scanning.
Conclusion
There has been rising interest in studying non-invasive
techniques of imaging cartilage tumours to try and deter-
mine their biologic aggressiveness prior to definitive sur-
gery. The advantages of functional nuclear scanning with
DMSA(V) and thallium are that they are easy to perform
in the majority of nuclear medicine departments, the iso-
topes are easily available and the costs are not prohibitive.
We have found that the information derived from our
study complements other imaging modalities and apart
from improving our understanding of cartilaginous
tumours, has also assisted us in developing a strategy for
their treatment.
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